Market outlook of the global pulmonary hypertension market
Pulmonary hypertension is an example of a rare disease that affects arteries carrying blood to the lungs. The narrowing, or blockage of these arteries results in pulmonary hypertension. The recent increase in the sales of ERAs that gained global acceptance due to its oral mode of administration is expected to aid this market in surpassing USD 4 billion by 2019.
Technavio’s market research analyst has estimated the Americas to account for more than 52% of the total market share by 2019. This region’s high market share can be attributed to factors such as the increasing focus on combination therapies and the recent increase in the number of geriatric population in this region during the forecast period.
Competitive landscape and key vendors
This market is highly competitive and is dominated by the presence of large vendors like Actelion, Bayer, GlaxoSmithKline, and United Therapeutics. The acceptance and launch of novel formulations is expected to propel the revenue generated by the vendors in this market.
Key leading vendors in this market are -
- United Therapeutics
Other prominent vendors analyzed in this market study are Aires Pharmaceuticals, Arena Pharmaceuticals, Bial, DEKA, Dong-A ST, Gilead, Merck, Northern Therapeutics, Novartis, Pfizer, PhaseBio, Radikal Therapeutics, Reata Pharmaceuticals, and SteadyMed.
Formulation-based segmentation of the pulmonary hypertension market
In this market analysis, Technavio’s market research analysts have estimated the oral segment to account for more than 70% of the total market share by 2019. This segment dominates the market as many companies prefer developing oral formulations as it does not involve widespread animal, and human efficacy and safety studies.
Segmentation by mechanism of action and analysis of the pulmonary hypertension market
- Endothelin receptor antagonists (ERAs)
- Prostacyclin analogs
- Phosphodiesterase inhibitors (PDE)
- Soluble guanylate cyclase stimulators (sGC)
The ERA segment accounts for almost 60% of the total market share by 2019 and aids in reducing high blood pressure by suppressing the pulmonary constriction. As endothelin is a 21-amino acid peptide involved in pulmonary vasoconstriction, drugs acting on them bind to ET-A and B receptors and reduce constriction.
Key questions answered in the report include
What will the market size and the growth rate be in 2019?
- What are the key factors driving the global pulmonary hypertension market?
- What are the key market trends impacting the growth of the global pulmonary hypertension market?
- What are the challenges to market growth?
- Who are the key vendors in the global pulmonary hypertension market?
- What are the market opportunities and threats faced by the vendors in the global pulmonary hypertension market?
- Trending factors influencing the market shares of APAC, EMEA, and the Americas?
- What are the key outcomes of the five forces analysis of the global pulmonary hypertension market?
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market size and forecast
Five forces analysis
PART 06: Pipeline portfolio
Key Information of the few pipeline candidates
PART 07: Market segmentation by type of formulation
PART 08: Market segmentation by mechanism of action
Endothelin receptor antagonist
Soluble guanylate cyclase stimulators
PART 09: Geographical segmentation
PART 10: Market drivers
Increase in incidence of pulmonary hypertension
Patient assistance programs
Newer disease modifying therapies
Unmet medical needs
PART 11: Impact of drivers
PART 12: Market challenges
Poor patient compliance
Intense competition among vendors
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on combination therapies
Increase in awareness of hypertension
PART 15: Vendor landscape
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors
PART 16: Key vendor analysis
PART 17: Appendix
List of abbreviation
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
- Collation of data
- Estimation of key figures
- Analysis of derived insights
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape